Summit Therapeutics Inc.

SMMTSEC EDGAR

Pharmaceutical PreparationsCIK: 1599298

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	$705.0K	$705.0K	$1.8M	$860.0K
Research and Development Expense	—	—	$52.0M	$85.4M	$53.3M
Operating Expenses	$609.6M	$87.2M	$87.2M	$109.0M	$73.4M
Operating Income (Loss)	—	-$72.1M	-$72.1M	-$86.2M	-$53.2M
Interest Expense	—	—	—	$242.0K	$255.0K
Nonoperating Income (Expense)	$11.2M	-$2.3M	-$6.7M	-$2.4M	$283.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$614.9M	-$78.8M	-$78.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$435.6M	$202.9M	$664.2M	$113.4M	$102.5M
Assets, Current	$423.8M	$189.7M	$656.7M	$97.3M	$87.7M
Cash and Cash Equivalents, at Carrying Value	$71.4M	$348.6M	$348.6M	$71.8M	—
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$349.0K	$1.5M	$331.0K
Liabilities	$46.8M	$125.3M	$537.5M	$30.1M	$23.0M
Liabilities, Current	$41.7M	$20.4M	$38.8M	$25.6M	$19.9M
Accounts Payable, Current	$4.6M	$2.7M	$355.0K	$4.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$76.8M	-$41.6M	-$41.6M	-$72.6M	-$48.1M
Net Cash Provided by (Used in) Investing Activities	-$587.8M	-$624.0K	-$624.0K	-$306.0K	-$421.0K
Net Cash Provided by (Used in) Financing Activities	$86.5M	$620.2M	$620.2M	$77.9M	$50.6M
Payments to Acquire Property, Plant, and Equipment	$128.0K	$624.0K	$624.0K	$306.0K	$421.0K
Payments of Dividends	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)